Studies further showed that the forced expression of IL-17A in the lung promotes tumor proliferation through IL-6 and tumor-associated neutrophils and that IL-17A mediates resistance to therapeutic programmed cell death protein 1 (PD-1) blockade [120,122]. Here, IL6 is linked to neoplasm.